Moreover, therapies that promote immune tolerance, such as allergen immunotherapy, reduce the proportion of IL-4–secreting CD8 + T cells in patients experiencing intermittent allergic rhinitis [187, 188], suggesting that downregulation of Tc2 responses is integral to its therapeutic mechanism. The gene discussed is IL4; the disease is allergic rhinitis.